|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
FSSAI files three adjudication cases against Nestle India
|
|
Monday, 21 September, 2026, 08 : 00 AM [IST]
|
|
Our Bureau, New Delhi
|
The Food Safety and Standards Authority of India (FSSAI) has formally filed three separate adjudication cases against Nestle India Ltd in respect of the three implicated products under the FSS Act, 2006.
The National Food Regulator has initiated legal adjudication proceedings against Nestle India Ltd (Unit I & Unit II) following multiple non-compliances across its prominent infant nutrition products, including NAN Excella Pro Stage 1, Lactogen Pro 1, and a Follow-up Formula product.
According to statutory enforcement disclosures released by the apex regulator, FSSAI carried out a detailed examination of Nestle India’s infant nutrition range and corresponding promotional material available across e-commerce platforms. The analysis revealed direct contraventions of food labelling standards, illegal marketing claims, and nutrient composition shortfalls.
As per FSSAI, regulatory examinations revealed that promotional material for NAN Excella Pro Stage 1 featured unapproved claims regarding "5 HMOs" and "Whey Protein", while promotional content for Lactogen Pro 1 carried claims asserting that "Whey Protein" is easy to digest.
Following initial notices, FSSAI determined that both products breached Regulation 4(2) of the FSS (Foods for Infant Nutrition) Regulations, 2020, which strictly restricts promotional claims intended to boost the saleability of infant foods. The practices were also found to violate Section 3 of the IMS Act 1992, which imposes a blanket prohibition on advertising and marketing infant formula.
In a parallel quality violation, FSSAI stated, laboratory analysis of a sample of Follow-up Formula manufactured by Nestle India declared the batch sub-standard due to non-compliant Biotin content.
After Nestle appealed the initial finding, the sample was referred to an accredited Referral Food Laboratory for re-analysis. The secondary testing corroborated the defect, confirming that the product failed to conform with prescribed Biotin requirement limits set under the FSS (Foods for Infant Nutrition) Regulations, 2020.
|
|
|
|
|
|
|
|
|
|